Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
September 14, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
August 07, 2023 08:30 ET
|
Evoke Pharma, Inc.
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize...
Evoke Pharma Reports First Quarter 2023 Financial Results
May 15, 2023 16:05 ET
|
Evoke Pharma, Inc.
Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE...
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
April 20, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
March 23, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
February 21, 2023 07:00 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
January 18, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Record Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET
|
Evoke Pharma, Inc.
80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 ...
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
September 20, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
September 14, 2022 08:30 ET
|
Evoke Pharma, Inc.
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey ...